U.S. President Donald Trump unveiled his “Great Healthcare Plan” Jan. 15, an initiative he said would slash prescription drug prices, maximize price transparency in the health care system and hold big insurance companies accountable. Read More
The EMA had its second busiest year ever in 2025, approving 104 drugs, of which 38 had a new active substance. Sixteen of these are for treating rare diseases, and four are advanced therapy medicinal products. Read More
At a pair of panels on developing and selling drugs in Europe at the Biotech Showcase 2026 meeting in San Francisco, experts discussed the good, the bad and the ugly parts of the European drug development scene. Read More
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype outweighed reality and in the end, no major merger announcements were made during the conference for companies developing therapeutics. Read More
For decades, scientists have searched for a mechanistic link between viral infection and multiple sclerosis (MS). Insights from three studies recently published in Cell bring that connection into sharper focus. By tracing how the immune system responds to Epstein-Barr virus (EBV) – and how those responses can misfire against the brain – researchers are beginning to uncover a compelling biological explanation for MS. Read More
Biopharma financing values have shown quarterly volatility over the past decade, with surges often concentrated in specific quarters rather than evenly distributed throughout the year. The pandemic era marked a clear inflection point, and more recently, financing patterns have normalized with outsized quarters driving annual totals. In 2025, total financings accelerated as the year progressed, rising from $13.12 billion in the first quarter (Q1) to $18.92 billion in Q3 to a peak of $33.16 billion in Q4, the strongest quarter since early 2024. Read More
A biostatistician who was consulting for C4 Therapeutics Inc. is facing civil and criminal charges of U.S. securities fraud related to insider trading that allegedly produced nearly $500,000 in profit. Read More
Biopharma happenings, including deals and partnerships, and other news in brief: Alloy, Bayer, Elpasbio, Fosun, Genethon, Novartis, Peplib, Pharmather, SL Bio, Tahoe. Read More
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Emergent, Immedica, Immunitybio, Ipsen, Sandoz, Travere. Read More
Effective Jan. 5, 2026, BioWorld is switching email fulfillment services. While we have made every effort to ensure that all current user subscription details — as well as information on users who have unsubscribed — have been migrated accurately to the new system, there may be a few instances where certain information may not have carried over as expected. If you have any concerns that you received a newsletter in error or if a colleague has not received an expected newsletter, do not hesitate to reach out to our customer care team. Call us:
Americas: 855-258-3279
Europe, Middle East, and Africa: +44 8081 963232
Going forward, if you would like to be unsubscribed, click on the ‘Unsubscribe’ link at the bottom of the emailed newsletter.
